Brian Cheng
Stock Analyst at JP Morgan
(2.26)
# 2,229
Out of 4,555 analysts
58
Total ratings
51.22%
Success rate
-6.74%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Brian Cheng
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ITOS iTeos Therapeutics | Maintains: Overweight | $27 → $24 | $15.56 | +54.24% | 2 | Aug 12, 2024 | |
| NTLA Intellia Therapeutics | Maintains: Overweight | $61 → $55 | $19.83 | +177.36% | 3 | Aug 12, 2024 | |
| IMVT Immunovant | Maintains: Overweight | $51 → $46 | $31.44 | +46.31% | 2 | Aug 8, 2024 | |
| XNCR Xencor | Maintains: Overweight | $30 → $27 | $19.89 | +35.75% | 3 | Jul 31, 2024 | |
| KYTX Kyverna Therapeutics | Maintains: Overweight | $39 → $33 | $7.38 | +347.15% | 2 | Jul 31, 2024 | |
| PTGX Protagonist Therapeutics | Maintains: Overweight | $39 → $48 | $44.59 | +7.65% | 3 | Jul 25, 2024 | |
| MGX Metagenomi | Downgrades: Neutral | $16 → $6 | $2.90 | +106.90% | 2 | May 2, 2024 | |
| IMNM Immunome | Initiates: Overweight | $24 | $14.62 | +64.16% | 2 | Apr 30, 2024 | |
| PGEN Precigen | Downgrades: Underweight | n/a | $0.97 | - | 2 | Mar 22, 2024 | |
| MRSN Mersana Therapeutics | Upgrades: Neutral | $5 | $1.50 | +233.33% | 3 | Mar 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $15 | $22.40 | -33.04% | 1 | Mar 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $8 | $2.48 | +222.58% | 3 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $8 → $9 | $3.51 | +156.41% | 2 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $23 | $21.34 | +7.78% | 1 | Dec 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $15 | $12.50 | +20.00% | 6 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $44 → $46 | $39.94 | +15.17% | 4 | Oct 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $14 | $1.82 | +669.23% | 3 | Sep 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $2.75 | - | 3 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $20 → $6 | $1.48 | +305.41% | 2 | Jun 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $8 → $9 | $11.70 | -23.08% | 1 | Mar 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $2.89 | - | 1 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $0.93 | - | 2 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $24 | $2.89 | +730.45% | 1 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | n/a | $1.51 | - | 1 | Sep 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $71 → $85 | $19.00 | +347.37% | 2 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | n/a | $7.67 | - | 1 | Aug 3, 2021 |
iTeos Therapeutics
Aug 12, 2024
Maintains: Overweight
Price Target: $27 → $24
Current: $15.56
Upside: +54.24%
Intellia Therapeutics
Aug 12, 2024
Maintains: Overweight
Price Target: $61 → $55
Current: $19.83
Upside: +177.36%
Immunovant
Aug 8, 2024
Maintains: Overweight
Price Target: $51 → $46
Current: $31.44
Upside: +46.31%
Xencor
Jul 31, 2024
Maintains: Overweight
Price Target: $30 → $27
Current: $19.89
Upside: +35.75%
Kyverna Therapeutics
Jul 31, 2024
Maintains: Overweight
Price Target: $39 → $33
Current: $7.38
Upside: +347.15%
Protagonist Therapeutics
Jul 25, 2024
Maintains: Overweight
Price Target: $39 → $48
Current: $44.59
Upside: +7.65%
Metagenomi
May 2, 2024
Downgrades: Neutral
Price Target: $16 → $6
Current: $2.90
Upside: +106.90%
Immunome
Apr 30, 2024
Initiates: Overweight
Price Target: $24
Current: $14.62
Upside: +64.16%
Precigen
Mar 22, 2024
Downgrades: Underweight
Price Target: n/a
Current: $0.97
Upside: -
Mersana Therapeutics
Mar 19, 2024
Upgrades: Neutral
Price Target: $5
Current: $1.50
Upside: +233.33%
Mar 4, 2024
Initiates: Outperform
Price Target: $15
Current: $22.40
Upside: -33.04%
Feb 27, 2024
Maintains: Overweight
Price Target: $9 → $8
Current: $2.48
Upside: +222.58%
Feb 27, 2024
Maintains: Neutral
Price Target: $8 → $9
Current: $3.51
Upside: +156.41%
Dec 5, 2023
Initiates: Overweight
Price Target: $23
Current: $21.34
Upside: +7.78%
Nov 14, 2023
Maintains: Overweight
Price Target: $16 → $15
Current: $12.50
Upside: +20.00%
Oct 12, 2023
Maintains: Neutral
Price Target: $44 → $46
Current: $39.94
Upside: +15.17%
Sep 25, 2023
Maintains: Overweight
Price Target: $17 → $14
Current: $1.82
Upside: +669.23%
Aug 10, 2023
Upgrades: Neutral
Price Target: n/a
Current: $2.75
Upside: -
Jun 1, 2023
Downgrades: Neutral
Price Target: $20 → $6
Current: $1.48
Upside: +305.41%
Mar 31, 2023
Maintains: Neutral
Price Target: $8 → $9
Current: $11.70
Upside: -23.08%
Dec 16, 2022
Initiates: Neutral
Price Target: n/a
Current: $2.89
Upside: -
Dec 7, 2022
Downgrades: Underweight
Price Target: n/a
Current: $0.93
Upside: -
Jan 7, 2022
Initiates: Overweight
Price Target: $24
Current: $2.89
Upside: +730.45%
Sep 2, 2021
Initiates: Overweight
Price Target: n/a
Current: $1.51
Upside: -
Aug 10, 2021
Maintains: Overweight
Price Target: $71 → $85
Current: $19.00
Upside: +347.37%
Aug 3, 2021
Initiates: Overweight
Price Target: n/a
Current: $7.67
Upside: -